Skip to content
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
Home/About Us

About Us

Your Window Into China’s Biotech Revolution

BioPharmChina is a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

China has emerged as one of the world’s most dynamic life sciences markets, driven by groundbreaking research, growing biotech innovation, expanding clinical development, and increasing global collaboration and partnerships. From innovative drugs and novel therapies to emerging biotech companies, clinical trials, regulatory developments, and investment, the pace of change is creating enormous opportunities—and challenges—for the global biopharmaceutical community.

Our mission is to help readers understand this transformation.

What We Cover

BioPharmChina.com delivers timely and insightful coverage across the Chinese biotech and pharmaceutical ecosystem, including:

  • Biotech & Biopharma News — The latest developments from China’s biotechnology and pharmaceutical industries.
  • Drug Development — Innovative therapies, clinical trials, drug pipelines, and R&D milestones.
  • Biotech Companies — Coverage of established pharmaceutical companies, emerging biotech startups, and innovative research organizations.
  • Regulatory & Policy — Updates from China’s regulatory environment and developments affecting drug development and commercialization.
  • Clinical Trials — Important clinical-stage developments and advances in China’s growing clinical research ecosystem.
  • Investment & Business — Funding rounds, partnerships, licensing deals, M&A, IPOs, and other major business developments.
  • Science & Innovation — Breakthrough research, new technologies, and scientific discoveries shaping the future of medicine.
  • Global Connections — China’s growing role in global drug development, licensing, partnerships, and pharmaceutical innovation.

Connecting China With the Global Biopharma Community

One of our goals is to make China’s rapidly developing biotech ecosystem easier to understand and follow for readers around the world.

We believe that some of the most important advances in medicine are increasingly coming from collaborations that cross geographic and organizational boundaries. Chinese biotech companies are developing innovative assets, forming partnerships with multinational pharmaceutical companies, and bringing new technologies and drug candidates into global development programs.

BioPharmChina.com aims to serve as a bridge between China’s life sciences community and the global biopharmaceutical industry.

Our Editorial Mission

We strive to provide accurate, timely, informative, and easy-to-understand coverage of China’s biotech and pharmaceutical sectors.

Our goal is not simply to report what happened, but to provide context that helps readers understand why it matters—whether you are a pharmaceutical professional, biotech investor, researcher, healthcare executive, entrepreneur, or simply interested in the future of biotechnology.

As the industry continues to evolve, we will continue to follow the companies, technologies, therapies, and people driving China’s biotech revolution.

BioPharmChina — Following China’s biotech revolution and its impact on global healthcare.

2026 H2 AbbVie China Partnering Day
2026 Global XDC Innovation Conference

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Latest Articles

  • Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
  • 1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
  • Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
  • Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
  • iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.

Info

    About

    Privacy Policy

    Terms of Use

    Newsletter

    Contact

    Contact

    Email
    contact@biopharmchina.com

    Location
    San Francisco, CA, USA

    • X
    • Facebook
    Copyright 2026 — BioPharmChina. All rights reserved.